GLEN ROCK, NJ--(Marketwired - Jul 12, 2016) - RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company's President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (www.cantor.com) in New York, New York on Wednesday, July 13, 2016, at 9:30 a.m. Eastern Time. The Conference is being sponsored by Cantor Fitzgerald & Co. and is being held at Le Parker Meridien Hotel, New York, New York, on July 12 and July 13, 2016.
Commented Dr. Manuso, "The presentation at the Cantor Fitzgerald Conference will provide RespireRx management with the opportunity to give investors an update on RespireRx's strategic initiatives and progress on research and development programs. I look forward to discussing the Company's Phase 2A clinical trial testing the impact of the oral ampakine, CX-1739, on opioid-induced respiratory depression."
Dr. Manuso will also discuss the Company's other product pipeline candidates, including dronabinol, and the Company's development timelines. Dr. Manuso concluded, "We are pleased to keep our shareholders and other stakeholders informed as to the continuing progress of RespireRx's scientific, clinical and regulatory development initiatives."
Dr. Manuso's slide presentation will be accessible after the presentation on RespireRx's web-site at www.respirerx.com, by clicking on the investors tab and following the links and instructions. A copy of the slide presentation being presented at the Cantor Fitzgerald Conference will be submitted in a Form 8-K filing with the U.S. Securities and Exchange Commission prior to the presentation.
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders, with a focus on sleep apneas and drug-induced respiratory depression. The Company holds exclusive licenses and owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
RespireRx's pharmaceutical candidates in development are derived from two platforms, as described below.
The first platform is the class of compounds known as cannabinoids, in particular, dronabinol. Under a license agreement with the University of Illinois, the Company has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol produced a statistically significant reduction in the Apnea-Hypopnea Index, the primary therapeutic end-point, and was observed to be safe and well-tolerated in a group of patients with Obstructive Sleep Apnea ("OSA"). The University of Illinois and three other centers are currently investigating dronabinol in a potentially pivotal, six week, double-blind, placebo-controlled Phase 2B clinical trial in 120 patients with OSA. The University of Illinois has indicated that recruitment for this clinical trial was completed during the second quarter of 2016. This clinical trial is fully funded by the National Heart, Lung and Blood Institute of the National Institutes of Health. The Company is not managing or funding this ongoing clinical trial.